INTRODUCTION: Numerous @entity251 (T) formulations are available, each with differing effects on serum parameters. AIM: The aim of this study was to compare the long-term effects of topical, injectable, and implantable pellet T formulations in hypogonadal @entity1 . METHODS: Retrospective review of hypogonadal @entity1 treated with a single T formulation was performed: 47 @entity1 on T gels, 57 on injectable T, and 74 on T pellets were identified. @entity348 ( @entity348 ), @entity5815 (FT), @entity53 (E), hemoglobin (Hgb), hematocrit (Hct), @entity1486 (PSA), total @entity165 (Tchol), @entity1674 (TG), low-density lipoprotein (LDL), and high-density lipoprotein (HDL) @entity165 were evaluated at baseline and every 3-6 months for 3 years. Serum parameters were compared using a mixed model linear regression for repeated measures. MAIN OUTCOME MEASURES: Effects of topical, injectable, and pellet T formulations on serum hormone levels, Hgb, Hct, lipid parameters and PSA. RESULTS: @entity1 in the injectable T group were younger (42.5        12.3 years) than in the gel (54.1        9.8 years) or pellet groups (53.8        13.0 years), and baseline FT, Hgb, and Hct were higher in the injectable T group than in gel or pellet groups. Increases in @entity348 and FT were observed throughout follow-up in all groups. Increases in E were observed at in all T groups and throughout follow-up in injectable and gel groups. No PSA increases were observed. Erythrocytosis (Hct   >   50%) was more common with injectable T (66.7%) than with T gels (12.8%) or pellets (35.1%, P   <   0.0001). Transient changes in @entity165 , TG, and LDL were observed, and no significant changes were seen in HDL for any group. CONCLUSIONS: All T formulations increase serum T and FT. More significant increases in E occur with injectable T and T gels. Changes in Hgb and Hct are most significant with injectable T, and effects on lipids are variable and inconsistent. Selection of T formulations must account for individual @entity1 preferences and the effects of each formulation.

Comparison of the Effects of @entity251 Gels, Injections, and Pellets on Serum Hormones, Erythrocytosis, Lipids, and XXXX .

@entity1 :: ('9606', 'Species') :: ['patient', 'Men', 'men'] @entity251 :: ('MESH:D013739', 'Chemical') :: ['testosterone'] @entity1674 :: ('MESH:D014280', 'Chemical') :: ['triglycerides'] @entity53 :: ('MESH:D004958', 'Chemical') :: ['estradiol'] @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol'] @entity348 :: ('MESH:C535338', 'Disease') :: ['TT', 'Total T'] @entity5815 :: ('MESH:D015673', 'Disease') :: ['calculated free T'] @entity1486 :: ('354', 'Gene') :: ['prostate-specific antigen']
@entity1486 :: (354,Gene) :: ['Prostate-Specific Antigen']
